Company Information
- Type:
- Company
- Country:
- France
- Sector:
- Pharmaceuticals & Biotechnology
- Ownership:
- Publicly Listed
- Global Compact Status:
- Active
- Participant Since
- 20 December 2012 Letter of Commitment
- Next Communication on Progress (COP) due on:
- 31 July 2025
Communication On Progress
| Published On | Title | Level/Status |
|---|---|---|
| 22-Jul-2024 | 2024 Communication on Progress | Submitted |
| 21-Dec-2023 | 2023 Communication on Progress | Submitted |
| 11-May-2022 | Communication on Progress IPSEN | Active |
| 20-May-2021 | Communication on Progress | Active |
| 28-May-2020 | Communication on Progress | Active |
| 29-May-2019 | Communication on Progress | Active |
| 29-May-2018 | 2018 Ipsen Registration Document Based on 2017 Performance | Active |
| 31-May-2017 | Communication on Progress | Active |
| 02-Mar-2017 | Communication on Progress | Active |
| 02-Mar-2016 | Communication on Progress | Active |
| 29-Feb-2016 | Communication on Progress | Active |
| 27-Oct-2014 | Communication on Progress IPSEN | Active |
| 22-Nov-2013 | Communication on Progress | Active |
Note: Responsibility for the content of participants' public communication related to the Ten Principles of the UN Global Compact and their implementation lies with participants themselves and not with the UN Global Compact.
Note on levels: Not applicable refers to the period when the Communication on Progress (CoP) did not require differentiation levels. With the new CoP , for the 2022 Early Adopter Programme, and for 2023, there will be no differentiation levels.